旋转斑块切除联合药物涂层球囊治疗股腘动脉病变的两年疗效:与单纯药物涂层球囊血运重建的比较
回顾性研究纳入2016年1月至2018年1月间121例症状性股腘动脉严重钙化病变患者(226处病变),比较旋转斑块切除(RA)联合药物涂层球囊(DCB)与单纯DCB的两年结果。RA+DCB组技术成功率更高(95.4% vs. 84.8%,P=0.006),补救性支架置入率更低(5.1% vs. 20.6%,P<0.001),12个月和24个月免于靶病变血运重建(TLR)率均显著提高(95.2% vs. 76.3%,P=0.002;93.4% vs. 63.7%,P=0.002)。
要点
- RA+DCB治疗股腘动脉严重钙化病变的技术成功率显著高于单纯DCB。
- RA+DCB显著降低补救性支架置入率和限流性夹层发生率。
- RA+DCB组12个月和24个月免于TLR率均显著优于单纯DCB组。
核心结论
- RA联合DCB是治疗复杂股腘动脉病变有效、安全且持久的方法。
- 与单纯DCB相比,RA+DCB技术成功率更高、限流性夹层更少、TLR和补救性支架置入率显著降低。
研究设计与样本
- 回顾性研究,纳入2016年1月至2018年1月间接受腔内治疗的121例症状性股腘动脉严重钙化病变患者,共226处病变。
- RA+DCB组58例患者、112处病变(49.5%);单纯DCB组63例患者、114处病变(50.5%)。
- 平均年龄61.2 ± 9.7岁;排除轻微或严重组织缺失患者;随访24个月。
主要发现
- RA+DCB组病变长度长于单纯DCB组(14.4 ± 5.2 cm vs. 10.2 ± 3.1 cm;P = 0.05)。
- RA+DCB组技术成功率95.4%,单纯DCB组84.8%(P = 0.006)。
- 12个月和24个月造影通畅率两组相似(85.7% vs. 74.6%;73.2% vs. 62.7%)。
- RA+DCB组补救性支架置入率5.1%(n=3),单纯DCB组20.6%(n=13),P < 0.001。
- RA+DCB组12个月和24个月免于TLR率分别为95.2%和93.4%,单纯DCB组分别为76.3%和63.7%(P = 0.002)。
关键数值与推荐
- 主要通畅率通过6、12、24个月双功超声/血管造影以及12、24个月血管造影评估。
- 限流性夹层发生率RA+DCB组3.4%(n=2),单纯DCB组12.6%(n=8),P < 0.001。
- 血管回缩发生率RA+DCB组1.7%(n=1),单纯DCB组6.3%(n=4),P < 0.002。
- 出院时踝肱指数改善RA+DCB组0.35 ± 0.24,单纯DCB组0.30 ± 0.23(P = 0.683)。
- 总体生存率RA+DCB组96.5%(56/58),单纯DCB组93.6%(59/63),1年和2年随访均相同。
临床怎么用
- 对于股腘动脉严重钙化且症状性病变,可考虑RA联合DCB以提升技术成功率和降低补救性支架置入。
- RA+DCB可能减少限流性夹层和血管回缩,从而降低TLR风险。
- 需注意RA+DCB组病变更长,应结合病变特征个体化选择。
局限性
- 回顾性研究设计。
- 样本量有限(121例患者,226处病变)。
- 两组病变长度存在差异(P = 0.05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to evaluate the results of the combined use of rotational atherectomy (RA) followed by drug-coated balloon (DCB) treatment against DCB angioplasty alone in patients who had significantly calcified and symptomatic femoropopliteal peripheral arterial disease. METHODS: Patients presented to the clinic with symptoms of chronic limb ischemia of femoropopliteal segment such as moderate or severe claudication and rest pain, who received endovascular therapy between January 2016 and January 2018 in our hospital comprised the study cohort and investigated, retrospectively. Patients with minor or major tissue loss were excluded from the study. We evaluated the effect of RA system followed by DCB with DCB alone in 121 patients and a total of 226 significantly calcified and symptomatic femoropopliteal lesions. Fifty-eight patients and 112 (49.5%) lesions were treated with RA + DCB, whereas 63 patients and 114 (50.5%) lesions were treated with DCB only. The mean age was 61.2 ± 9.7 years. Primary patency is evaluated with duplex ultrasound/angiography at 6, 12, and 24 months and with angiography on 12 and 24 months. Patients were followed up for 24 months to assign clinically driven target lesion revascularization (TLR). Overall survival rates were 96.5% (56/58) in RA + DCB group and 93.6% (59/63) in DCB alone group both at one-year and two-year follow-up. Amputation-free survival rates of RA + DCB and DCB-only groups are 96.5% (56/58) to 87.3% (55/63) at one year, and 94.8% (55/58) to 82.5% (52/63) at two years, respectively. RESULTS: Baseline characteristics of groups were similar. The lesions were longer in the RA + DCB group than the DCB alone group (14.4 ± 5.2 cm vs. 10.2 ± 3.1 cm; P = 0.05). The technical success rate in the RA + DCB group was superior to that of DCB-only group (95.4% vs. 84.8%, P = 0.006). The 12-month and 24-month patency rates with angiography in the RA-DCB group were similar to those in the DCB-only group (85.7% vs. 74.6% and 73.2% vs. 62.7%, respectively). The rates of bailout stenting were significantly lower among patients treated with RA + DCB (n = 3; 5.1% vs. n = 13; 20.6%, P < 0.001). The rates of flow-limiting dissections and vessel recoils after procedures were significantly in RA + DCB group (n = 2; 3.4% vs. n = 8; 12.6%, P < 0.001) than DCB only (n = 1; 1.7% vs. n = 4; 6.3%, P < 0.002). The freedom from TLR rate was significantly increased in the RA + DCB group at 12 months (95.2% vs. 76.3%, P = 0.002) and 24 months (93.4% vs. 63.7%, P = 0.002). The mean ankle brachial index at discharge in the RA-DCB group improved by 0.35 ± 0.24, and in the DCB-only group, it was 0.30 ± 0.23 (P = 0.683). CONCLUSIONS: Combined use of RA and DCB treatment is an effective, safe, and durable method for the treatment of the complex femoropopliteal lesions. Combination of RA and DCB angioplasty reveals increased technical success, fewer flow-limiting dissections, significantly reduced TLR, and bailout stenting rates compared with sole DCB angioplasty.
引用
- Rodoplu O, Oztas DM, Meric M, et al. Efficacy of Rotational Atherectomy Followed by Drug-coated Balloon Angioplasty for the Treatment of Femoropopliteal Lesions-Comparison with Sole Drug-coated Balloon Revascularization: Two-year Outcomes. Ann Vasc Surg. 2021. PMID: 33359329. doi:10.1016/j.avsg.2020.10.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。